Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vesiculobullous Skin Disease Clear all
Withdrawn Not applicable Interventional

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

NCT02795143
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Isotretinoin, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

NCT00683930
View directory record Official record
Conditions
Pemphigus Vulgaris (PV)
Interventions
Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jul 21, 2026, 11:36 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

NCT02613910
View directory record Official record
Conditions
Pemphigus
Interventions
Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 21, 2026, 11:36 PM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
4 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 21, 2026, 11:36 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

NCT00483119
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
intravenous immunoglobulin, cyclophosphamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05267600
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
efgartigimod PH20 SC, placebo, Prednisone
Biological · Other · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Fountain Valley, California • Redwood City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pro-Resolving Mediators in Acute Inflammation in Humans

NCT04308889
View directory record Official record
Conditions
Inflammation; Skin, Resolution, Blister
Interventions
Lovaza, Cantharone, Phlebotomy
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Jul 21, 2026, 11:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers

NCT00001150
View directory record Official record
Conditions
Dermatitis, Healthy, Neoplasm, Urticaria, Vesiculobullous Skin Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1976 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 11:36 PM EDT
Terminated Phase 1 Interventional Results available

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

NCT03239470
View directory record Official record
Conditions
Pemphigus Foliaceus, Pemphigus Vulgaris
Interventions
Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
San Francisco, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

NCT00472030
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Omalizumab, prednisone
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

NCT03536143
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Topical beremagene geperpavec, Placebo gel
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT03752905
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01, Normal saline
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Redwood City, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 21, 2026, 11:36 PM EDT
Terminated Phase 1 Interventional

Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders

NCT00278642
View directory record Official record
Conditions
Pemphigus
Interventions
Hematopoietic stem cell transplantation
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Jul 21, 2026, 11:36 PM EDT
Withdrawn No phase listed Observational

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

NCT04214002
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 2 Interventional

Use of KC706 for the Treatment of Pemphigus Vulgaris

NCT00606749
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
KC706
Drug
Lead sponsor
Kemia, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Jul 21, 2026, 11:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

NCT06834035
View directory record Official record
Conditions
Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
Immunoglobulin G
Biological
Lead sponsor
M. Peter Marinkovich
Other
Eligibility
6 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Results available

Ixekizumab in the Treatment of Bullous Pemphigoid

NCT03099538
View directory record Official record
Conditions
Bullous Pemphigoid, Pemphigoid
Interventions
Ixekizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

NCT00584935
View directory record Official record
Conditions
Ocular Cicatricial Pemphigoid
Interventions
Rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

NCT01033552
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Cyclophosphamide, Fludarabine, Anti-thymocyte globulin, Myeloablative Busulfan, Mesenchymal stem cell transplantation, Total body irradiation, Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 21, 2026, 11:36 PM EDT
Not yet recruiting Phase 1 Interventional

Subconjunctival Humira for Boston Keratoprosthesis

NCT06926478
View directory record Official record
Conditions
Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Interventions
Adalimumab Injection
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 1 Interventional

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

NCT02793960
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
topical BPM31510 3.0% Cream
Drug
Lead sponsor
Shasa Hu
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jul 21, 2026, 11:36 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa

NCT04213703
View directory record Official record
Conditions
Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Dystrophica
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 21, 2026, 11:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

MSC EVs in Dystrophic Epidermolysis Bullosa

NCT04173650
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
AGLE-102
Drug
Lead sponsor
Aegle Therapeutics
Industry
Eligibility
6 Months and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jul 21, 2026, 11:36 PM EDT
Recruiting Phase 1 Interventional

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417
View directory record Official record
Conditions
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Interventions
RAY121
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 11:36 PM EDT